CrystalGenomics Invites Past Earnings Performance
Past criteria checks 0/6
CrystalGenomics Invites's earnings have been declining at an average annual rate of -28.6%, while the Biotechs industry saw earnings growing at 9.2% annually. Revenues have been growing at an average rate of 0.1% per year.
Key information
-28.6%
Earnings growth rate
-25.7%
EPS growth rate
| Biotechs Industry Growth | 11.7% |
| Revenue growth rate | 0.1% |
| Return on equity | -33.2% |
| Net Margin | -965.3% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How CrystalGenomics Invites makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 4,879 | -47,093 | 23,835 | 7,182 |
| 30 Sep 23 | 42,763 | -27,758 | 28,375 | 6,242 |
| 30 Jun 23 | 41,607 | -52,693 | 30,301 | 6,556 |
| 31 Mar 23 | 39,263 | -25,518 | 28,005 | 6,255 |
| 31 Dec 22 | 4,321 | -21,658 | 17,002 | 6,305 |
| 30 Sep 22 | 37,556 | -29,993 | 28,880 | 5,840 |
| 30 Jun 22 | 40,631 | -25,947 | 24,411 | 5,915 |
| 31 Mar 22 | 43,839 | -19,657 | 22,292 | 5,688 |
| 31 Dec 21 | 42,376 | -15,901 | 21,566 | 4,859 |
| 30 Sep 21 | -65,378 | -18,308 | 10,653 | 4,158 |
| 30 Jun 21 | -39,375 | -2,442 | 13,412 | 2,741 |
| 31 Mar 21 | -4,812 | -4,499 | 15,921 | 2,779 |
| 31 Dec 20 | 30,223 | -12,885 | 16,147 | 4,980 |
| 30 Sep 20 | 125,485 | -25,519 | 23,084 | 5,471 |
| 30 Jun 20 | 92,402 | -44,831 | 18,207 | 5,471 |
| 31 Mar 20 | 54,619 | -46,251 | 13,929 | 5,471 |
| 31 Dec 19 | 14,007 | -37,616 | 9,191 | 4,849 |
| 30 Sep 19 | 9,313 | 355 | 4,841 | 3,269 |
| 30 Jun 19 | 9,090 | 3,360 | 4,594 | 3,269 |
| 31 Mar 19 | 14,020 | 9,588 | 4,700 | 3,473 |
| 31 Dec 18 | 13,887 | 6,860 | 4,995 | 3,435 |
| 30 Sep 18 | 9,466 | -4,872 | 5,696 | 6,295 |
| 30 Jun 18 | 12,471 | -3,205 | 5,640 | 6,295 |
| 31 Mar 18 | 9,668 | -8,422 | 6,908 | 6,192 |
| 31 Dec 17 | 12,175 | -8,575 | 6,948 | 7,539 |
| 30 Sep 17 | 10,887 | -7,066 | 1,641 | 12,052 |
| 30 Jun 17 | 10,530 | -7,738 | 2,092 | 12,052 |
| 31 Mar 17 | 13,459 | -5,128 | 1,982 | 10,918 |
| 31 Dec 16 | 14,525 | -1,960 | 5,980 | 7,066 |
| 30 Sep 16 | 15,357 | 1,006 | 5,430 | 6,102 |
| 30 Jun 16 | 14,433 | 769 | 5,074 | 6,102 |
| 31 Mar 16 | 9,120 | -1,673 | 4,088 | 6,102 |
| 31 Dec 15 | 6,136 | -4,992 | 2,956 | 6,102 |
| 30 Sep 15 | 6,831 | -8,454 | 10,095 | 6,558 |
| 30 Jun 15 | 5,230 | -10,489 | 7,727 | 6,558 |
| 31 Mar 15 | 5,274 | -10,243 | 2,423 | 6,558 |
| 31 Dec 14 | 4,536 | -11,931 | 3,095 | 6,558 |
| 30 Sep 14 | 6,075 | -9,970 | -5,542 | 6,658 |
| 30 Jun 14 | 5,677 | -10,349 | -2,825 | 6,658 |
| 31 Mar 14 | 5,168 | -12,438 | 3,730 | 6,658 |
| 31 Dec 13 | 4,796 | -11,406 | 2,995 | 6,658 |
| 30 Sep 13 | 2,193 | -13,609 | 9,336 | 1,155 |
| 30 Jun 13 | 2,362 | -13,307 | 9,530 | 1,155 |
Quality Earnings: A083790 is currently unprofitable.
Growing Profit Margin: A083790 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: A083790 is unprofitable, and losses have increased over the past 5 years at a rate of 28.6% per year.
Accelerating Growth: Unable to compare A083790's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: A083790 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (28.8%).
Return on Equity
High ROE: A083790 has a negative Return on Equity (-33.18%), as it is currently unprofitable.